TWD 51.5
(-2.83%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 280.88 Million TWD | 304.48% |
2022 | 69.44 Million TWD | 96.03% |
2021 | 35.42 Million TWD | -18.44% |
2020 | 43.43 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 469.45 Million TWD | 67.14% |
2024 Q2 | 244.7 Million TWD | -47.88% |
2023 Q3 | 114.82 Million TWD | 5.36% |
2023 FY | 280.88 Million TWD | 304.48% |
2023 Q1 | 70.72 Million TWD | 1.84% |
2023 Q2 | 108.98 Million TWD | 54.1% |
2023 Q4 | 280.88 Million TWD | 144.62% |
2022 Q4 | 69.44 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Allied Biotech Corporation | 910.11 Million TWD | 69.138% |
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | 0.586% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | 52.392% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 91.662% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 92.257% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 95.776% |
Center Laboratories, Inc. | 6.78 Billion TWD | 95.861% |
Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | -74.404% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | 68.518% |
InnoPharmax Inc. | 48.64 Million TWD | -477.362% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | 12.496% |
Excelsior Biopharma Inc. | 472.87 Million TWD | 40.601% |
DV Biomed Co., Ltd. | 765.87 Million TWD | 63.325% |
Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | 54.471% |
UniPharma Co., Ltd. | 37.4 Million TWD | -650.999% |
Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | 72.336% |
Alar Pharmaceuticals Inc. | 76.08 Million TWD | -269.148% |
Winston Medical Supply Co., Ltd. | 373.87 Million TWD | 24.873% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | -464.914% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | -158.277% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | -110.199% |